BackVertex Pharmaceuticals Overview
Vertex Pharmaceuticals, Inc.

Vertex Pharmaceuticals Target Price

See Vertex Pharmaceuticals's analyst price targets ($570) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$523.93

Average Target Price

$573.189.4% upside

17 analysts in the last 4 months

High: $665 | Low: $350

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-10-08RBC Capital$5769.9% upsideOpen
2026-09-28UBS$61517.4% upsideOpen
2026-09-23JefferiesAkash Tewari$64022.2% upsideOpen
2026-09-22H.C. WainwrightAndrew Fein$64122.3% upsideOpen
2026-09-01Morgan StanleyTerence Flynn$66526.9% upsideOpen
2026-09-01Goldman Sachs$65324.6% upsideOpen
2026-08-11BernsteinJeffrey Walch$60816% upsideOpen
2026-08-10Wolfe ResearchAndy Chen$5627.3% upsideOpen
2026-08-05Truist Financial$5657.8% upsideOpen
2026-08-05Barclays$61717.8% upsideOpen
2026-08-04Stifel Nicolaus$5004.6% downsideOpen
2026-08-04Canaccord Genuity$44215.6% downsideOpen
2026-08-04Cantor Fitzgerald$59513.6% upsideOpen
2026-07-13Truist Financial$5606.9% upsideOpen
2026-07-13UBS$58511.7% upsideOpen
2026-07-07RBC Capital$5708.8% upsideOpen
2026-07-07Robert W. Baird$35033.2% downsideOpen
2026-05-27Truist FinancialDanielle Brill$5423.4% upsideOpen
2026-05-06Barclays$61517.4% upsideOpen
2026-05-05Bernstein$5729.2% upsideOpen
2026-05-05RBC CapitalBrian Abrahams$5433.6% upsideOpen
2026-05-05Morgan Stanley$61617.6% upsideOpen
2026-05-05Canaccord Genuity$43616.8% downsideOpen
2026-04-30Canaccord Genuity$43716.6% downsideOpen
2026-04-10Morgan Stanley$61216.8% upsideOpen
2026-03-10Truist FinancialJoon Lee$5250.2% upsideOpen
2026-03-10JefferiesAkash Tewari$58010.7% upsideOpen
2026-03-02BMO CapitalEvan David Seigerman$60014.5% upsideOpen
2026-02-17H.C. WainwrightAndrew Fein$59112.8% upsideOpen
2026-02-17BarclaysEliana Merle$60715.9% upsideOpen
2026-02-17Canaccord Genuity$44115.8% downsideOpen
2026-02-13Morgan StanleyTerence Flynn$5708.8% upsideOpen
2026-02-13Cantor Fitzgerald$59012.6% upsideOpen
2026-02-13Stifel NicolausPaul Matteis$46611.1% downsideOpen
2026-02-13RBC Capital$5413.3% upsideOpen
2026-02-13Bernstein$57710.1% upsideOpen
2026-02-13ScotiabankLouise Chen$5586.5% upsideOpen
2026-02-13H.C. WainwrightAndrew Fein$5181.1% downsideOpen
2026-01-27Barclays$60615.7% upsideOpen
2026-01-26UBS$5454% upsideOpen
2026-01-23Evercore ISICory Kasimov$5301.2% upsideOpen
2026-01-22RBC CapitalBrian Abrahams$5464.2% upsideOpen
2026-01-06UBSMichael Yee$5352.1% upsideOpen
2025-12-29Leerink Partners$5250.2% upsideOpen
2025-12-05Morgan Stanley$5647.6% upsideOpen
2025-12-03Morgan StanleyTerence Flynn$5161.5% downsideOpen
2025-11-04BarclaysGena Wang$41421% downsideOpen
2025-11-04Stifel Nicolaus$44515.1% downsideOpen
2025-11-04Cantor FitzgeraldCarter Gould$4857.4% downsideOpen
2025-11-04RBC Capital$41520.8% downsideOpen

Vertex Pharmaceuticals (VRTX) FAQ

Vertex Pharmaceuticals posts a target price of $570. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $570 for VRTX means covering analysts, on average, see the stock 9.4% upside of $523.93 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for VRTX's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Vertex Pharmaceuticals's other metric pages and overview cover the third.

Judging Vertex Pharmaceuticals against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $570 here, then scan peer and history charts to see if the gap is persistent.